CClinicalTrials.gg
CompletedNCT03414905Updated Feb 20, 2024

Management of Malignant Pleural Effusions Using an Indwelling Tunneled Pleural Catheter and Non-Vacuum Collection System

An observational study in Malignant Pleural Effusion, sponsored by Washington University School of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Washington University School of Medicine · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Study summary

In this study, the investigators will collect data on patients who are using the Aspira system as part of their clinical care for the management of recurrent pleural effusion. Data will be collected on patient demographics, placement of the pleural catheter, palliation of dyspnea, complication rates, and rates of spontaneous pleurodesis.

02

Conditions studied

  • Malignant Pleural Effusion
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The participants will be seen at Washington University School of Medicine.

Inclusion criteria

  • Male or female, at least 18 years of age, inclusive
  • Subject has a symptomatic malignant pleural effusion requiring intervention. For an effusion to be defined as malignant, at least one of the following must be true

    • There is cytological confirmation of pleural malignancy
    • The effusion is an exudate (per Light's criteria Pleural fluid protein/Serum protein >0.5, Pleural fluid LDH/Serum LDH >0.6, or Pleural fluid LDH >2/3 the upper limit of normal) in the context of histocytologically proven malignancy elsewhere, with no other clear cause for fluid identified
  • Subject is able to provide informed consent
  • Subject has sufficient pleural fluid to allow safe insertion of an indwelling tunneled pleural catheter as determined by the PI
  • Subject is able to perform home drainage of the pleural effusion or has sufficient resources (family member, caregiver, home health).

Exclusion criteria

Exclusion Criteria:

  • Subject is pregnant
  • Subject has evidence, in the opinion of the PI, of either ongoing systemic or pleural infection
  • Subjects with uncorrected coagulopathy
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (actual)
Patient registry
No

Groups and cohorts

  • Aspira Catheter & Drainage System

    * Participants will have standard of care ultrasound and placement of the Aspira Catheter and Drainage System on Day 1 * The removal of the Aspira Catheter and Drainage System will be dependent upon future ultrasound assessment and fluid output

    Device: Aspira Catheter · Procedure: Ultrasound

Interventions

  • DeviceAspira Catheter

    * 15.5Fr catheter * Standard of care

    Also known as: Aspira Catheter and Drainage System

  • ProcedureUltrasound

    Standard of care

05

What researchers measure

Primary outcomes

  1. Relief of dyspnea as measured using the Visual Analog Scale for Dyspnea (VAS-Dyspnea)

    * This will be determined based on the difference between the VAS-Dyspnea score on the day of catheter insertion prior to catheter insertion compared with the VAS-Dyspnea score on the 2 week follow up visit * The scale presents the question "how much shortness of breath are you having right now?" with a straight line. At one end it states "no shortness of breath" and the other end is "shortness of breath as bad as can be". The participant will mark the line on how they feel * No shortness is breath is 0% score and shortness of breath as bad as can be is 100% score

    Time frame: Through 2 weeks following catheter insertion

Secondary outcomes

  1. Rate of infection

    -Defined as the isolation of any bacteria within a pleural fluid specimen drawn for clinical purposes

    Time frame: 1 year

  2. Rate of spontaneous pleurodesis

    -Defined as pleural fluid drainage less than 75ml every other day for three consecutive drainage sessions

    Time frame: 1 year

06

Study locations

1 site
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
07

References and documents

08

Registry details

Key details

Study ID
NCT03414905
Lead sponsor
Washington University School of Medicine
Collaborators
Merit Medical Systems, Inc.
Responsible party
Sponsor
First posted
Jan 30, 2018
Start date
Jul 9, 2018
Primary completion
Sep 26, 2023
Completion
Feb 15, 2024
Last update
Feb 20, 2024

Study contacts

Alexander Chen, M.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion